Results 161 to 170 of about 29,994,236 (203)

Histone Deacetylase Inhibitors (HDACis) as Latency-Reversing Agents in HIV Cure Strategies: Chemistry, Selectivity, and Clinical Perspective. [PDF]

Viruses
Almolhim H.
europepmc   +1 more source

Editorial: HIV-1 Tat, an enhancer of virus infectivity and disease promoter: target for preventive and therapeutic interventions. [PDF]

Front Immunol
Cafaro A, Karn J, Berkhout B, Valente S, Ensoli B.   +4 more
europepmc   +1 more source

Hijacking the Host: Post-Translational Modifications as Molecular Switches in HIV Persistence and Immune Evasion. [PDF]

J Med Virol
Arrambide CAJ, Karampoor S, Abdelrahim IM, Maloletneva NV, Mirzaei R.   +4 more
europepmc   +1 more source

Central Nervous System Reservoirs and HIV Cure: Therapeutic Opportunities and Challenges. [PDF]

Curr HIV/AIDS Rep
Angelovich TA, Roche M, Gorry PR, Churchill MJ.   +3 more
europepmc   +1 more source

Distinct roles of dopamine receptors in HIV latency reversal in a myeloid cell model. [PDF]

Front Immunol
Basova LV, Riley T, Delorme-Walker V, de Siqueira-Lima D, Milner R, Ellis RJ, Fox H, Marcondes MCG.   +7 more
europepmc   +1 more source

Persistent IFN-I signaling associated with the HIV-1 reservoir fuels immune exhaustion and reveals therapeutic targets. [PDF]

Front Immunol
Zhang Z, Ren P, Deng M, Li Q, Chen Z.
europepmc   +1 more source

A screen of chromatin-targeting compounds identifies TAF1 as a novel regulator of HIV latency. [PDF]

mBio
Burgos SD, Ward AM, Ashokkumar M, Enders KP, James LI, Margolis DM, Browne EP.   +6 more
europepmc   +1 more source

Latent HIV Reservoirs in the Central Nervous System: Mechanisms, Barriers, and Therapeutic Approaches. [PDF]

ACS Infect Dis
Matthew Y, Foley N, Claiborne DT, Klase Z, Dick A.   +4 more
europepmc   +1 more source

Solving a BAF'ling Problem : pharmacological Reversal of HIV-1 Latency

, 2019
openaire   +1 more source